BlossomHill Therapeutics
- Market cap
- 527.95M
- P/E (TTM)i
- -6.80
- P/Bi
- -3.02
- EPSi
- -3.69
- Div yieldi
- 0.00%
- 52W posi
- 11%
Anonymous reader poll. Unscientific, not investment advice.
About BlossomHill Therapeutics
BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying its intentional, chemistry-based approach to develop small molecule medicines that address unmet medical needs in cancer treatment. Its product pipeline includes two clinical-stage programs: BH-30643, an investigational, non-covalent, macrocyclic, brain active, mutant-selective OMNI-EGFR inhibitor for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), and BH-30236, an investigational macrocyclic CDC-like kinase (CLK) inhibitor being evaluated first in relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndromes (HR-MDS), and the preclinical-stage product candidate BH-501284 targeting activated KRAS.
- CEO
- Dr. J. Jean Cui
- Employees
- 63
- Fiscal year end
- 12-31
- Website
- bhtherapeutics.com
Company profile
- Exchange
- US
- Symbol
- BLSM
- Market-cap rank
- #3711
- Listing date
- 2026-08-07
- Market cap
- 527.95M
- Float cap
- 155.72M
- Shares out
- 31.78M
- Float shares
- 9.38M
Sectors & themes
Quote time 2026-10-08 04:52:37 · For reference only, not investment advice and not tailored to your situation.